CD19-CAR T细胞治疗儿童及年轻成人B-ALL的长期随访
中位随访4.8年,中位OS为10.5个月;MRD阴性CR后桥接alloHSCT者中位OS达70.2个月,5年EFS为61.9%。
要点
- CD19.28ζ-CAR T细胞在复发/难治性B-ALL儿童及年轻成人中完全缓解率达62.0%。
- 氟达拉滨/环磷酰胺清淋者CR率69%,高于非氟达拉滨/环磷酰胺清淋者的25%。
- MRD阴性CR后序贯alloHSCT可获持久疾病控制,5年EFS为61.9%。
核心结论
- CD19.28ζ-CAR T细胞序贯alloHSCT可使相当比例复发/难治性B-ALL儿童及年轻成人获得持久疾病控制。
主要发现
- 中位随访4.8年,中位OS为10.5个月(95%CI 6.3-29.2个月)。
- alloHSCT后24个月累积复发率为9.5%(95%CI 1.5-26.8),5年EFS为61.9%(95%CI 38.1-78.8)。
临床怎么用
- 对复发/难治性B-ALL儿童及年轻成人,可考虑CD19.28ζ-CAR T细胞治疗后桥接alloHSCT以改善长期结局。
- 清淋方案宜优先选择氟达拉滨/环磷酰胺为基础的方案以提高完全缓解率。
局限性
- alloHSCT亚组分析非随机比较,存在选择偏倚可能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: CD19 chimeric antigen receptor (CD19-CAR) T cells induce high response rates in children and young adults (CAYAs) with B-cell acute lymphoblastic leukemia (B-ALL), but relapse rates are high. The role for allogeneic hematopoietic stem-cell transplant (alloHSCT) following CD19-CAR T-cell therapy to improve long-term outcomes in CAYAs has not been examined. METHODS: We conducted a phase I trial of autologous CD19.28ζ-CAR T cells in CAYAs with relapsed or refractory B-ALL. Response and long-term clinical outcomes were assessed in relation to disease and treatment variables. RESULTS: Fifty CAYAs with B-ALL were treated (median age, 13.5 years; range, 4.3-30.4). Thirty-one (62.0%) patients achieved a complete remission (CR), 28 (90.3%) of whom were minimal residual disease-negative by flow cytometry. Utilization of fludarabine/cyclophosphamide-based lymphodepletion was associated with improved CR rates (29/42, 69%) compared with non-fludarabine/cyclophosphamide-based lymphodepletion (2/8, 25%; P = .041). With median follow-up of 4.8 years, median overall survival was 10.5 months (95% CI, 6.3 to 29.2 months). Twenty-one of 28 (75.0%) patients achieving a minimal residual disease-negative CR proceeded to alloHSCT. For those proceeding to alloHSCT, median overall survival was 70.2 months (95% CI, 10.4 months to not estimable). The cumulative incidence of relapse after alloHSCT was 9.5% (95% CI, 1.5 to 26.8) at 24 months; 5-year EFS following alloHSCT was 61.9% (95% CI, 38.1 to 78.8). CONCLUSION: We provide the longest follow-up in CAYAs with B-ALL after CD19-CAR T-cell therapy reported to date and demonstrate that sequential therapy with CD19.28ζ-CAR T cells followed by alloHSCT can mediate durable disease control in a sizable fraction of CAYAs with relapsed or refractory B-ALL (ClinicalTrials.gov identifier: NCT01593696).
引用
- Shah NN, Lee DW, Yates B, et al. Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL. J Clin Oncol. 2021. PMID: 33764809. doi:10.1200/JCO.20.02262
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。